ArticleBMC cancer2026
Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trop-2 expression is associated with poor survival in pleural mesothelioma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited treatment options. Recently, GATA3 has emerged as a useful adjunct immunohistochemical marker, especially for non-epithelioid subtypes. Although the diagnostic and prognostic roles of GATA3 have been described in other malignancies, its frequency and clinical relevance in MPM remains unclear.
methodsWe conducted a retrospective, single-center cohort study of 91 patients with histologically confirmed MPM and suitable tumor tissue for GATA3 immunohistochemistry. Staining intensity was scored semi-quantitatively (mild, moderate, or strong). Clinical, pathological, and treatment data were collected. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier methods and Cox regression models.
resultsGATA3 expression was observed in 64 of 91 cases (70.3%). No differences in PFS or OS were observed according to GATA3 positivity. GATA3 positivity demonstrated the ability to discrimine MPM and LUAD, with area under the curve (AUC) values of 0.83 for overall MPM, 0.81 for epithelioid MPM, and 0.93 for non-epithelioid MPM. The diagnostic performance was further improved by Combining GATA3 with WT1, yielding AUC values of 0.94 for MPM, 0.93 for epithelioid MPM, and 1.00 for non-epithelioid MPM. High GATA3 staining intensity was associated with shorter median PFS (6.14 vs. 10.94 months; p = 0.023) and OS (7.89 vs. 33.35 months; p = 0.004) compared with cases showing low or moderate intensity. High GATA3 staining intensity remained an independent adverse prognostic factor for OS (HR 6.59; 95% CI 1.55–28.05; p = 0.011) in a multivariate analysis adjusted for asbestos exposure, ECOG PS, clinical stage, PD-L1 positivity, and histological type.
conclusionGATA3 is frequently expressed in MPM and demonstrates good diagnostic performance differentiating MPM from LUAD. Furthermore, high GATA3 staining intensity was independently associated with a poorer prognosis. These findings support GATA3 diagnostic utility and suggest a potential prognostic role in MPM that warrants validation in larger, prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.